PDA

View Full Version : Articles of Interest

Pages : 1 2 3 4 5 6 7 8 9 10 11 12 [13] 14 15 16 17 18
  1. GM-CSF as therapy
  2. Herceptin (Traztuzumab)
  3. Local therapy for metastases
  4. PET/CT Shows Tumor Response to Trastuzumab
  5. Bezielle (BZ101) oral botanical
  6. Altered serotonin physiology in human bc favors paradoxical growth and cell survival
  7. HER2 Status Predicts Recurrence of Small Breast Cancers
  8. Activin/Nodal signaling results in invasive bc cells arising from non-invasive bc
  9. Hearing sensitivity in women following chemotherapy treatment for breast cancer
  10. Immediate Postmastectomy Reconstruction Tied to Better Breast Cancer Survival
  11. pRb loss predicts good outcome in triple negative breast cancer
  12. Ku proteins contribute to ERBB2 overexpression in breast cancer
  13. Vitamin D
  14. Pertuzumab
  15. mTOR inhibitors
  16. Pain From Breast Cancer Treatment Can Linger For Years, Study Finds
  17. GcMAF: vitamin D-binding protein-derived macrophage-activating factor
  18. Trigonelline stimulates ER (roasted coffee ingredient)
  19. Glucocorticoids
  20. HDAC Histone deacetylation inhibitors
  21. Anthracycline Cardiotoxicity Appears Limited in Breast Cancer in the Short Term
  22. USPSTF Issues New Breast Cancer Screening Guidelines
  23. Specialized Radiation Offers No Survival Benefit in Early Breast Cancer
  24. Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor in BC CTC's
  25. Data on Off-Label Targeted Cancer Drugs More Plentiful Than Helpful
  26. Growth Colony stimulation as chemo suppport
  27. Study: Discriminatory Accuracy of Prognosis Calculation of Adjuvant!
  28. JX-593: targeted and armed oncolytic and immunotherapeutic poxviruse
  29. Gemcitabine
  30. Sunitinib
  31. Chemo Combinations/sequences with oomph
  32. Neuropathy
  33. Temporal concurrence of vasculitis and cancer: a report of 12 cases.
  34. Anti-prolactins
  35. Aloe
  36. Mucositus
  37. Determining Her2 status
  38. Fever therapy
  39. Managing cardio-toxicity
  40. Vitamin C
  41. Taxol treatment can result in delayed chronic neuropathy
  42. Novel Biomarkers May Enhance Cancer Therapy (HER2+ covered)
  43. Opiates/Opioids
  44. Brain mets
  45. Estrogen Receptor-Alpha, Breast Cancer Patients And Tamoxifen Response
  46. Trastuzumab Prolongs Survival in HER2+ Metastatic Breast Cancer
  47. Insulin potentiated therapy (IPT)
  48. What is skin metastasis?
  49. Fasting to enhance chemo
  50. Treatment Resistance: Preventing, Reversing
  51. Mammography May Increase Breast Cancer Risk In Some High-Risk Women
  52. Medial tumor localization in breast cancer--an unappreciated risk factor?
  53. Chloroquine (s)
  54. Combining Nanotubes And Antibodies For Breast Cancer 'Search And Destroy' Missions
  55. Elastography Imaging During Breast Ultrasound Reduces Unnecessary Biopsy Rate
  56. Serum calcium levels are elevated among women with untreated postmenopausal breast ca
  57. Fucoidan
  58. Histamine
  59. Navelbine
  60. Cancer Rehab: reconditioning to resume therapy
  61. Neoplastic meningitis (spinnal mets)
  62. Prolonged exposure to passive smoke may increase breast cancer risk
  63. Decline In Breast Cancer: Not Just Because Of Hormone Therapy
  64. CDK inhibitors as potential therapeutics for ER+/ and/or Her2+ bc
  65. Single-fraction schedules of Radiotherapy for Painful Bone Mets Underutilized
  66. Platinum and Bisplatinates
  67. Pixantrone (anthracycline with less cardiac impact)
  68. BC progression model recapitulates hypermethylation events associated w/premalignacy
  69. Life as an oncologist
  70. ER+ issues
  71. Transforming Growth Factor Beta May Control Breast Cancer Metastasis
  72. Do not read Tololos messages
  73. Grapefruit juice
  74. Milk thistle
  75. Poorer Prognosis for Heavy Women With Breast Cancer
  76. Tamoxifen following chemotherapy improves breast cancer outcome
  77. Specialized Radiation Offers No Survival Benefit in Early Breast Cancer
  78. T-DM1 Shrinks Tumors
  79. Diagnosing Breast Cancer: Needle Biopsy Best?
  80. Balance is everything - Her2+ mentioned
  81. Chemo brain research results
  82. Novel breast tissue feature linked to breast cancer risk
  83. DHA may improve breast cancer chemotherapy outcome
  84. Cranberries
  85. Apples
  86. Hypoxia-Inducible Factor (HIF)
  87. Her2-like & Basal like Genotype BC are more likely to respond to chemo
  88. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
  89. Leaving Home Early: Reexamination of the Canonical Models of Tumor Progression
  90. Cancer Center Ads Use Emotion More Than Fact
  91. Old Ideas Spur New Approaches in Cancer Fight
  92. Stellate Ganglion Block for Severe Hot Flashes
  93. Extended Aromatase Inhibitor Therapy Warranted In Premenopausal Breast Cancer
  94. Artemisinin (anti-malarial, anti-cancer)
  95. Vitamin E
  96. Bone mets
  97. PREDICT: a new UK prognostic model for breast cancer survival
  98. Physician Expectations of Treatment Outcomes from Whole Brain Radiation
  99. TEAM Trial: 5 Years of Aromatase Inhibitor Equal to Sequential Therapy
  100. Acupuncture vs Venlafaxine for Hormone-Therapy−Induced Hot Flashes
  101. Investigational Agent Reduces Tumor Resistance To Breast Cancer Therapy
  102. A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer
  103. The rapidly changing management of metastatic breast cancer
  104. An open conversation on metastatic breast cancer
  105. Pomegranate
  106. Mango
  107. Letrozole (Femara)
  108. supplement combinations
  109. Lung mets
  110. Ashwagandha (Withania somnifera)
  111. Cyclophosphamide
  112. Nigella Sativa (black cumin)
  113. Ertumaxomab
  114. Aryl-Hydrocarbon Receptor (AhR)
  115. PIPKI Gamma modulates invasion and proliferation; correlates with Her2+ and ER-
  116. Developing a gene expression profile to detect bc in peripheral blood
  117. Green tea polyphenol sensitizes bc cells to paclitaxel in mice
  118. Risk of Breast Cancer Death Higher in Patients on Paroxetine and Tamoxifen
  119. Testosterone, Vitamin D May Improve Aromatase Inhibitor Joint Problems
  120. Motherwort
  121. Hyperthermia for Breast Cancer
  122. Chemo+endocrine, endocrine + endocrine
  123. Editorial on bc stem cell markers
  124. Exemestane (Aromasin)
  125. acute myeloid leukemia (AML)
  126. Researches find Cyclin D1 required for self-renewal of Her2+ bc cells in mice
  127. HER2, TOP2A, and TIMP-1 and Responsiveness to Anthracyline tx
  128. Capsaicin (red pepper)
  129. Capecitabine (Xeloda)/5FU
  130. looking for an article on radiation
  131. Liver mets
  132. Antiangiogenic agents
  133. Research/study issues
  134. Honokiol (from magnolia)
  135. Garcinol/Garcinia indica
  136. Resveratrol
  137. Glucosamine
  138. Personalized Cancer Care Off to Slow Start (Questions Tamoxifen CYP2D6 testing)
  139. Cocoa
  140. Second solid cancers after breast cancer not linked to radiotherapy
  141. FDA Approves Lapatinib/Letrozole Combination for Advanced Breast Cancer
  142. Neoadjuvant Trastuzumab Benefits Women With HER2+ Inflammatory or Locally Advanced BC
  143. Finnish treatment breakthrough reduces breast cancer deaths by a third
  144. Lack of Evidence for Fracture Prevention in Early Breast Cancer Bisphosphonate Trials
  145. Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate:The SABRE Trial
  146. Salmonella
  147. Personalized Cancer Care Off to Slow Start
  148. Pleural effusions
  149. Antibiotics
  150. Pertuzumab Useful for Trastuzumab-Resistant HER2-Positive Breast Cancer
  151. Prolactin Blocks Oncogene Associated With Poor Prognosis In Breast Cancer
  152. Chemoresistance
  153. Review of Advances in tx for Her2+ metastatic bc
  154. Radiation
  155. Seliciclib/Roscovitine
  156. Elephant's foot (Elephantopus scaber L)
  157. Promotion of variant human mammary epithelial cell outgrowth by ionizing
  158. Familial relative risks for breast cancer by pathological subtype
  159. 10-Year Results of Hypofractionated Radiation for Breast Cancer
  160. Should Oncologists Test for CYP2D6 Before Prescribing Tamoxifen?
  161. Radiation Oncologists Announce Six-Point Plan for Safer Radiotherapy
  162. Proton pump inhibitors (PPI)
  163. Selenium
  164. Chemosensitivity prediction
  165. Master Gene SRC-3 Enables Breast Cancer Growth, Invasion
  166. Survival, multi-lineage potency of bc initiating cells treated with rx
  167. Aspirin Benefit Seen in Existing BC
  168. Cancer origins (theories and research)
  169. Blocking EGFR receptor sensitizes bc cells to Her2 therapy
  170. 'Revolutionary' DNA Test for Cancer Hailed
  171. Boron (Boric acid)
  172. Vitamin D Kills Breast Cancer Cells
  173. Significant Effect of Polymorphisms Clinical Outcomes of Tamoxifen Therapy
  174. Bitter Melon Extract Attacks Breast Cancer Cells
  175. Scientists Unlock Key To Tamoxifen Resistance
  176. 2009 San Antonio Breast Cancer Symposium: Potentially Practice-Changing Studies, Pt 1
  177. 2009 San Antonio Breast Cancer Symposium: Potentially Practice-Changing Studies, Pt 2
  178. How to stay sane fighting cancer
  179. FDA show by John Stossel
  180. Lasofoxifene Helps Reduce Risk Of Bone Fractures, BC, Heart Disease And Stroke
  181. Sentinal Node Micromets linked to pooer BC Survival
  182. Gene test predicts effectiveness of Paclitaxel
  183. Researchers find no link between Cox2 inhibitor use and reduced bc risk
  184. Bitter melon/Karela (Momordica charamtia)
  185. Personalized Blood Test Can Track Tumor-Specific Markers After Therapy
  186. Miscellaneous side effects
  187. The role of soy on breast cancer risk and survival
  188. New way tx her2...
  189. Osteoporosis Drugs Are Associated With A Decrease In Risk Of Breast Cancer
  190. "Terrorist Cells" in Mar. 15, 2010 Forbes Mag.
  191. Lovastatin (a statin) has potential to reduce growth of bc cells
  192. Test for chemo sensitivity based on DNA repair proteins
  193. Primary Care Providers Uneasy on Cancer Survivorship Care
  194. Financial Hardship: A Frequent Side Effect of Cancer
  195. Green Tea/epigallocatechin-3-gallate (EGCG)
  196. Thiamine (Vitamin B-1) supplementation and cancer
  197. New trial to test Malaria drug on DCIS
  198. Risk of Recurrent Disease in HER2-Positive Patients
  199. Aspiration of Breast Lumps Reviewed
  200. Genetic variation in ER metabolic pathway not correlated with breast density
  201. Mapping proteomic pathways in MBC to tailor treatment
  202. 3-D ultrasound dx bc in dense breasts
  203. Familiar Risk related to tumor subtype
  204. From the NEJM: The Missing Voice of Patients in Drug-Safety Reporting
  205. From the NEJM: Individual Genomes on the Horizon
  206. Coexpression of HSP90 & PI3K or expression of HSP90 w/loss of PTEN predicts RFS in H2
  207. interesting article on protein signaling....
  208. Next Generation...
  209. Bad news on biphosphonates for longer than four years use...
  210. BC mets, tau, and Taxol
  211. Cancer and the Media
  212. Breast Cancer Treated by Freezing Tumors
  213. Tests for genes don't predict breast cancer better
  214. Liposomal taxanes en route
  215. Blocking Gene Ages Cancer Cells (skp2)
  216. Radioactive seeding could replace wire localization for bc surgery
  217. Entrapernurial Approach to Curing BC
  218. NIH studying progesterone to treat traumatic brain injuries
  219. Probe molecules give early answer to tx effectiveness
  220. Pertuzumab plus trastuzumab for Her2+ MBC
  221. Biomarkers Consortium Launches Adaptive Trial to Test Targeted Breast Cancer Drugs
  222. BC mortality in organised mammography screening in Denmark: comparative study
  223. Effect of Aromatherapy Massage in Patients with Breast Cancer
  224. From the NEJM: Bisphosphonates and Fractures of the Femur
  225. next generation of cancer research
  226. Use of Some SSRIs With Tamoxifen Increases Mortality in Breast Cancer Patients
  227. Targeting Signal Transduction Pathways in MBC: A Comprehensive Review
  228. CEP17 seems to predict anthracycline benefit
  229. Serum HER and EGFR testing
  230. Beta Blockers May Slow Spread of Breast Cancer
  231. Pemetrexed (Alimta)
  232. Ukrain/Celandine
  233. Treating the Her2-Positive Breast Cancer Patient
  234. New Research on Tamoxifen Resistance
  235. Review Paper on Signaling Pathways; Her2+ and ER+ discussed
  236. Identification of Subtypes in Her2+ BC Reveals a Gene Signature Prognostic of Outcome
  237. Locoregional Recurrence Remains Strong Outcome Predictor 10 Years After Lumpectomy
  238. Berberine/goldenseal
  239. Patient/Doctor Expectations of Metastatic Breast Cancer Treatments at Odds
  240. Longer Breastfeeding linked to More Aggressive Breast Cancer
  241. Can Metastatic Breast Cancer Be Cured?
  242. ZIOPHARM Commences Oral Indibulin Phase I/II Trial In Breast Cancer
  243. New Research in UK promising
  244. Workforce Shortages in Breast Imaging: Impact on Mammography Utilization
  245. Can Herceptin Wipe Out Cancer Stem Cells?
  246. Tykerb Can Reverse Herceptin Resistance
  247. Questions re HER2 Testing
  248. MicroRNA Responsible for Herceptin Resistance
  249. Sulforaphane (from broccoli)
  250. Two Options for Breast Cancer Prevention